(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Anger as German family business group opens talks with far-right AfD - 2Figure out How to Back Your Rooftop Substitution
- 3Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 4Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- 5Sources: IDF does not actually know how many ballistic missiles Iran has left
- Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- Scientists document a death from a meat allergy tied to certain ticks
- COGAT discovers motor oil hidden inside UN's humanitarian aid to Gaza in smuggling attempt
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- Picking Childcare Administrations for Your Loved ones
- When darkness shines: How dark stars could illuminate the early universe
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- 7 Delightful Ferris Wheels, Do You Like Them?
- Artemis II astronauts arrive in Florida to prepare for launch to the moon
